Table 2.
Clinical parameter | NLR | PLR | MLR | |||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
≤1.70 (102) | >1.70 (200) | χ 2 | P | ≤96 (76) | >96 (226) | χ 2 | P | ≤0.20 (84) | >0.20 (218) | χ 2 | P | |
Sex | 14.70 | <0.001∗ | 6.21 | 0.013∗ | 20.44 | <0.001∗ | ||||||
Male | 70 | 174 | 54 | 190 | 54 | 190 | ||||||
Female | 32 | 26 | 22 | 36 | 30 | 28 | ||||||
Age | 0.05 | 0.831 | 2.40 | 0.122 | 0.70 | 0.403 | ||||||
≤60 | 39 | 79 | 24 | 94 | 36 | 82 | ||||||
>60 | 63 | 121 | 52 | 132 | 48 | 136 | ||||||
Grade | 0.61 | 0.737 | 0.66 | 0.720 | 5.63 | 0.060 | ||||||
Well | 6 | 9 | 5 | 10 | 8 | 7 | ||||||
Moderately | 71 | 135 | 52 | 154 | 57 | 149 | ||||||
Poorly | 25 | 56 | 19 | 62 | 19 | 62 | ||||||
Tumour size | 3.15 | 0.076 | 3.63 | 0.057 | 0.35 | 0.552 | ||||||
≤5 cm | 77 | 131 | 59 | 149 | 60 | 148 | ||||||
>5 cm | 25 | 69 | 17 | 77 | 24 | 70 | ||||||
T stage | 7.00 | 0.072 | 6.15 | 0.104 | 5.66 | 0.130 | ||||||
Tis-T1 | 20 | 23 | 16 | 27 | 18 | 25 | ||||||
T2 | 15 | 18 | 11 | 22 | 9 | 24 | ||||||
T3 | 39 | 97 | 28 | 108 | 37 | 99 | ||||||
T4 | 28 | 62 | 21 | 69 | 20 | 70 | ||||||
N stage | 2.20 | 0.533 | 2.50 | 0.476 | 5.62 | 0.132 | ||||||
N0 | 46 | 76 | 36 | 86 | 42 | 80 | ||||||
N1 | 22 | 42 | 14 | 50 | 18 | 46 | ||||||
N2 | 19 | 41 | 15 | 45 | 12 | 48 | ||||||
N3 | 15 | 41 | 11 | 45 | 12 | 44 | ||||||
AJCC TNM stage | 7.85 | 0.020∗ | 7.01 | 0.030∗ | 7.22 | 0.027∗ | ||||||
I | 32 | 35 | 23 | 44 | 26 | 41 | ||||||
II | 30 | 64 | 27 | 67 | 28 | 66 | ||||||
III | 40 | 101 | 26 | 115 | 30 | 111 | ||||||
Vascular invasion | 1.23 | 0.267 | 0.78 | 0.376 | 4.18 | 0.041∗ | ||||||
No | 94 | 176 | 70 | 200 | 80 | 190 | ||||||
Yes | 8 | 24 | 6 | 26 | 4 | 28 | ||||||
SIRI | 99.23 | <0.001∗ | 29.16 | <0.001∗ | 89.02 | <0.001∗ | ||||||
≤0.68 | 79 | 37 | 49 | 67 | 68 | 48 | ||||||
>0.68 | 23 | 163 | 27 | 159 | 16 | 170 | ||||||
PLR | 26.42 | <0.001∗ | — | — | 22.03 | <0.001∗ | ||||||
≤96 | 44 | 32 | — | — | 37 | 39 | ||||||
>96 | 58 | 168 | — | — | 47 | 179 | ||||||
NLR | — | — | 26.42 | <0.001∗ | 48.43 | <0.001∗ | ||||||
≤1.70 | — | — | 44 | 58 | 54 | 48 | ||||||
>1.70 | — | — | 32 | 168 | 30 | 170 | ||||||
MLR | 48.43 | <0.001∗ | 22.03 | <0.001∗ | — | — | ||||||
≤0.20 | 54 | 30 | 37 | 47 | — | — | ||||||
>0.20 | 48 | 170 | 39 | 179 | — | — |
AJCC: American Joint Committee on Cancer; SIRI: systemic inflammation response index; PLR: platelet lymphocyte ratio; NLR: neutrophil lymphocyte ratio; MLR: monocyte lymphocyte ratio.